Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 19/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865485 | 0.96 | GRPR (0.71) | GRPR | |
| SCHEMBL29356178 | 0.94 | GRPR (0.76) | GRPR | |
| SCHEMBL14364817 | 0.86 | GRPR (0.78) | GRPR | |
| SCHEMBL14364818 | 0.86 | GRPR (0.78) | GRPR | |
| SCHEMBL30798936 | 0.85 | GRPR (0.81) | GRPR | |
| SCHEMBL16314443 | 0.85 | GRPR (0.76) | GRPR | |
| SCHEMBL14390132 | 0.85 | GRPR (0.76) | GRPR | |
| SCHEMBL31738157 | 0.85 | GRPR (0.76) | GRPR | |
| SCHEMBL12914181 | 0.85 | GRPR (0.76) | GRPR | |
| SCHEMBL31592157 | 0.85 | GRPR (0.76) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| CN-120199407-A | Pharmacogenomic decision support for modulators of NMDA, glycine and AMPA receptors | 密歇根大学董事会 | 2025-06-24 | — | — | CN | claimed |
| CN-113632174-B | Pharmacogenomic decision support for modulators of NMDA, glycine and AMPA receptors | 密歇根大学董事会 | 2025-03-25 | — | — | CN | claimed |
| US-12173063-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | AVENCELL EUROPE GMBH (DE) | 2024-12-24 | — | — | US | claimed |
| US-12176087-B2 | Pharmacogenomic decision support for modulators of the NMDA, glycine, and AMPA receptors | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-12-24 | — | — | US | claimed |
| US-20240409662-A1 | ANTIBODY MASKS AND USES THEREOF | VIBRANT PHARMA LIMITED (CN) | 2024-12-12 | — | — | US | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | claimed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | claimed |
| EP-4111201-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-20220073919-A1 | THERAPEUTIC OLIGONUCLEOTIDES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | GRPR 1137/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | GRPR 3070/4885 |
| US-12173063-B2 | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders | CD74, HAVCR2, CD4 | GRPR 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.